Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CONVERGE-HF
NCT06601465Phase 2Recruiting
- Sponsor
- University of Alberta
- Start
- Jun 2025
- Primary completion
- Jul 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of Vericiguat oral suspension (Formulation 4) in heart failure (HF) and cognitive impairment (2 arms), sponsored by University of Alberta. Primary endpoint: Change in the lateral ventricular volumes at 26 weeks. Started Jun 2025; status: recruiting.
02
Drugs
Vericiguat oral suspension (Formulation 4)
03
Conditions
heart failure (HF)cognitive impairment
Beyond the preview
Go deeper on NCT06601465.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06601465.